Quince Therapeutics (NASDAQ:QNCX – Get Free Report) released its earnings results on Monday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09), Zacks reports. The firm had revenue of $0.17 million for the quarter.
Quince Therapeutics Trading Down 2.1 %
QNCX opened at $1.37 on Wednesday. The company has a market cap of $60.28 million, a P/E ratio of -1.10 and a beta of 0.71. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The business’s 50-day simple moving average is $1.49 and its 200-day simple moving average is $1.44.
Wall Street Analyst Weigh In
A number of brokerages recently commented on QNCX. Brookline Capital Management started coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price objective on the stock. Oppenheimer initiated coverage on Quince Therapeutics in a report on Monday. They set an “outperform” rating and a $10.00 target price for the company. Finally, D. Boral Capital dropped their price target on shares of Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $8.00.
About Quince Therapeutics
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Recommended Stories
- Five stocks we like better than Quince Therapeutics
- 3 Small Caps With Big Return Potential
- Healthy Energy Drinks? Celsius Holdings Building Out the Space
- Upcoming IPO Stock Lockup Period, Explained
- Occidental’s Billion-Dollar Carbon Credit Plan Takes Shape
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Airship AI: Why This AI Penny Stock Is Poised for a Big Breakout
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
